Table 1.
Patient disease and transplant characteristics
| Variables | HCT with G-CSF | HCT without G-CSF | P-value |
|---|---|---|---|
| Number | 459 | 415 | |
| Age, years | 0·02 | ||
| 18-49 | 66 (14%) | 85 (20%) | |
| 50-80 | 393 (86%) | 330 (80%) | |
| Sex | 0·32 | ||
| Male | 284 (62%) | 243 (59%) | |
| Female | 175 (38%) | 172 (41%) | |
| Karnofsky Performance Status (KPS) | 0·62 | ||
| 90-100 | 250 (54%) | 237 (57%) | |
| <90 | 201 (44%) | 178 (43%) | |
| Not reported | 8 (2%) | - | |
| Hematopoietic cell transplant co-morbidity | 0·04 | ||
| ≤2 | 200 (43%) | 209 (51%) | |
| ≥3 | 258 (56%) | 205 (49%) | |
| Not reported | 1 (<1%) | 1 (<1%) | |
| Body mass index | 0·27 | ||
| 18-24.9 | 127 (28%) | 99 (24%) | |
| 25 - 29.9 | 176 (38%) | 159 (38%) | |
| 30 - 34.9 | 100 (22%) | 88 (21%) | |
| ≥35 | 55 (12%) | 67 (16%) | |
| Not reported | 1 (<1%) | 2 (<1%) | |
| Disease type | 0·56 | ||
| Acute myeloid leukemia | 207 (45%) | 179 (43%) | |
| Myelodysplastic syndrome | 252 (55%) | 236 (57%) | |
| Disease risk index | 0·94 | ||
| Low | 21 (5%) | 18 (4%) | |
| Intermediate | 232 (51%) | 217 (52%) | |
| High | 196 (43%) | 176 (42%) | |
| Not reported | 10 (2%) | 4 (1%) | |
| Donor type | 0·03 | ||
| HLA-matched sibling | 58 (13%) | 31 (7%) | |
| HLA-matched unrelated | 352 (77%) | 330 (80%) | |
| 1-locus HLA-mismatched unrelated | 49 (11%) | 54 (13%) | |
| Conditioning regimen * | 0·99 | ||
| Myeloablative | |||
| Fludarabine + busulfan + ATG | 145 (32%) | 109 (26%) | |
| Busulfan + cyclophosphamide + ATG | 33 (7%) | 39 (9%) | |
| Total body irradiation + fludarabine + ATG | 18 (4%) | 29 (7%) | |
| Reduced intensity | |||
| Fludarabine + busulfan + ATG | 171 (37%) | 145 (35%) | |
| Fludarabine + melphalan + ATG | 60 (13%) | 65 (16%) | |
| Total body irradiation + fludarabine + ATG | 32 (7%) | 28 (7%) | |
| Graft vs. host disease prophylaxis | 0·13 | ||
| Calcineurin inhibitor + methotrexate | 313 (68%) | 263 (63%) | |
| Calcineurin inhibitor + mycophenolate | 146 (32%) | 152 (37%) | |
| Transplant period | 0·38 | ||
| 2010-2013 | 155 (34%) | 152 (37%) | |
| 2014-2018 | 304 (66%) | 263 (63%) |
Median total ATG dose per kg (IQR) by regimen: HCT with G-CSF: Myeloablative: Fludarabine + busulfan + ATG: 4·0 (4·0, 5·0); Busulfan + cyclophosphamide + ATG: 5·0 (3·5, 5·0); Total body irradiation + fludarabine + ATG: 5·0 (4·5, 6·0). Reduced intensity: Fludarabine + busulfan + ATG: 6·0 (4·0, 6·5); Fludarabine + melphalan + ATG: 4·0 (4·0, 5·0); Total body irradiation + fludarabine + ATG: 3·75 (3·0, 4·5). HCT without G-CSF: Myeloablative: Fludarabine + busulfan + ATG: 4·5 (4·0, 5·0); Busulfan + cyclophosphamide + ATG: 5·0 (4·0, 6·0); Total body irradiation + fludarabine + ATG: 4·5 (4·0, 5·0). Reduced intensity: Fludarabine + busulfan + ATG: 5·0 (4·5, 6·0); Fludarabine + melphalan + ATG: 4·5 (3·5, 5·5); Total body irradiation + fludarabine + ATG: 4·5 (3·5, 4·5).
Abbreviation:
HCT = hematopoietic cell transplant
G-CSF = granulocyte colony stimulating factor
ATG = rabbit derived anti-thymocyte globulin